Janssen Pharmaceuticals’ Diabetes Medications Invokana and Invokamet Will Now Require Black-Box Warnings

Shared from Law360, New York (May 16, 2017, 6:29 PM EDT) — The U.S. Food and Drug Administration on Tuesday said it has confirmed that Janssen Pharmaceuticals’ diabetes medications Invokana and Invokamet can increase the risk of patients needing to have their legs or feet amputated and said the drugs will now require black-box warnings. The agency…

Details

Nearly 1/3 of All FDA Approved Medications Pose Safety Risks Identified Only After Approval

The Washington Post (5/9, McGinley, 11.43M) recently reported on a study published in the Journal of the American Medical Association suggesting that “almost a third of drugs cleared by the Food and Drug Administration pose safety risks that are identified only after their approval.” 222 products were reviewed that had been approved between 2001 and…

Details

Xarelto Litigation Updates

To date there have been 15,000 cases filed in the MDL. The first two trials will be held in the Eastern District of Louisiana. The first trial, The matter of Boudreaux, Joseph J. Jr., is scheduled to begin on April 24, 2017. The Plaintiff, Joseph Boudreaux was prescribed Xarelto to reduce the risk of stroke…

Details